Inside a lab that will open in a couple of months in Chicago, a biotech startup will soon begin perfecting the process of 3D-printing human hearts that could eventually be used in transplants.
The process combines several steps that have been developed by various researchers in university labs. First, a patient’s heart will be scanned using an MRI machine to create a digital image of the heart’s shape and size.
Next, doctors will take a blood sample. Using techniques that have been developed over the last decade, the blood cells will be converted into stem cells–and then converted a second time into heart cells.
Those new heart cells will be combined with nutrients in a hydrogel to make a “bio-ink” that can be used in a specialized 3D printer.
Printing one layer at a time, with a biodegradable scaffolding to keep everything in place, the cells can be formed into the exact shape of the patient’s original heart.
The new heart will be moved to a bioreactor to strengthen it. Amazingly, new heart cells outside a body will begin to self-assemble.
When the heart is strong enough, technicians will raise the temperature to melt the scaffolding around the cells.
The new heart can then be transplanted–and because it is the exact size of a patient’s original heart, and made from the patient’s own cells, it has a greater chance of success than a traditional transplant.
In studies, other researchers have successfully transplanted stem cells in both humans and animals without the need for anti-rejection drugs.
Most people who receive heart transplants now don’t live more than a decade. Their body may reject the organ directly.
The drugs they take to suppress their immune system–in an attempt to prevent the body from rejecting the foreign organ–may also make them unable to fight off another disease, such as cancer.
The Biolife4D heart, in contrast, won’t require patients to take immunosuppressant drugs since it is an exact genetic match.
The company isn’t the only startup in the space. A startup called Prellis Biologics, for example, has another printing process that is optimized for speed, and that includes blood vessels.
A company called Organovo already makes 3D printed human tissue for drug discovery. But Biolife4D may be the only startup to use equity crowdfunding.
The company has opened up investment to the public. “We wanted to make [the investment opportunity] available to everybody, not just wealthy people on Wall Street,” Morris says.
Please like, share and tweet this article.
Pass it on: New Scientist